AUS
NZ
UK
CA
USA
IND
Highlights
- SPRQ-Nx chemistry is projected to reduce sequencing expenses by up to 40%.
- Beta testing on Revio begins in November 2025; commercial release planned for 2026.
- Vega platform to introduce rapid sequencing runs and compliance upgrades next year.
PacBio (NASDAQ:PACB) announced significant updates to its Revio and Vega sequencing platforms, introducing the new SPRQ-Nx chemistry designed to increase cost efficiency and broaden multiomic capabilities.
The company said the new chemistry could decrease sequencing costs for high-throughput users by up to 40%, lowering the per-genome cost to under USD 300. SPRQ-Nx was developed to provide PacBio’s most economical HiFi genome data while preserving the precision and depth that defines its sequencing technology.
PacBio also highlighted advancements such as 5hmC detection for epigenetic research and new features aligned with 21 CFR Part 11 compliance on the Vega system. These enhancements are aimed at supporting large-scale population studies, clinical applications, and production-level workflows.
Beta Testing and Launch Schedule
Beta testing of the SPRQ-Nx chemistry on the Revio system will commence in November 2025, with commercial availability targeted for 2026. Beta participants will have access to sequencing reagents sufficient for 384 genomes, with an estimated cost of USD 250 per genome.
Revio instruments equipped with SPRQ-Nx will support multiple runs per SMRT Cell without reducing per-run data output. This design seeks to improve throughput, cut consumable waste, and sustain PacBio’s hallmark sequencing accuracy.
“With lower sequencing costs, deeper biological insights, and new capabilities for clinical research and production-scale labs, we are delivering on our goal to make HiFi sequencing accessible for every genome and every lab,” said Christian Henry, President and Chief Executive Officer of PacBio.
Vega Platform Updates and Regulatory Enhancements
The Vega benchtop sequencer is set to integrate SPRQ-Nx chemistry and 5hmC detection in 2026. Planned additions include rapid sequencing modes offering two- and four-hour runs, aimed at applications such as plasmid and targeted sequencing.
Vega will also feature upgraded security tools, including authentication and audit logging, to bolster operations within regulated research environments.
Continued Platform Support
PacBio reaffirmed its long-term commitment to both the Revio and Vega systems through 2032, supporting the growing demand for HiFi sequencing in extended and large-scale genomic studies.
